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Pr esen tation of C a se
Dr. Sherry Chou (Neurology): A 24-year-old woman was transferred to this hospital 
because of seizures and a lesion in the brain.
A diagnosis of systemic lupus erythematosus (SLE) had been made 6 years earlier, 
associated with polyarthritis, myalgia, malar rash, facial swelling, photosensitivity, 
pancytopenia, fevers, Raynaud’s syndrome, pericardial and pleural effusion, mem-
branous glomerulonephritis, and alopecia. She had been treated continuously with 
corticosteroids, with the addition of methotrexate, azathioprine, mycophenolate, 
leflunomide, and etanercept at various times, and dapsone prophylaxis. Her compli-
ance with her medication regimen had been poor, and she had stopped taking dap-
sone 6 months earlier.
For several months, the patient had experienced intermittent numbness of her 
tongue and slurred speech. Two weeks before admission, she was hospitalized else-
where because of fever (peak temperature, 39.4°C) and joint pain. A diagnosis of 
lupus flare was made; her symptoms responded to dexamethasone, and she was 
discharged home.
Six days before admission to this hospital, she had transient tingling and shaking 
of her right arm. The next day, she had a generalized tonic–clonic seizure and was 
admitted to another hospital. Treatment with diphenylhydantoin was started, and no 
additional seizures occurred. Magnetic resonance imaging (MRI) of the brain re-
vealed a small ovoid lesion in the left parietal lobe. Laboratory-test results are sum-
marized in Table 1. Stains, cultures, and tests for antigens in the cerebrospinal fluid 
were negative for bacteria, mycobacteria, cryptococcus, Neisseria meningitidis, Streptococ-
cus pneumoniae, group B streptococcus, and influenza B virus. The tingling in her right 
arm continued, and pain and weakness developed. A repeated MRI scan on the fourth 
hospital day showed enlargement of the lesion in the brain, with vasogenic edema 
involving the subcortical white matter of the left frontal and parietal lobes. Treat-
ment with ceftriaxone and acyclovir was started. The patient was transferred to 
this hospital 6 days after admission to the other hospital.
Case 39-2006: A 24-Year-Old Woman 
with Systemic Lupus Erythematosus, 
Seizures, and Right Arm Weakness
Jang-Ho J. Cha, M.D., Ph.D., Karen Furie, M.D., Jonathan Kay, M.D., 
Rochelle P. Walensky, M.D., M.P.H., Mark E. Mullins, M.D., Ph.D., 
and E. Tessa Hedley-Whyte, M.D.
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The patient had a history of depression. She had 
been treated for narcotic and alcohol dependency 
in the past, but did not currently use either intra-
venous drugs or alcohol to excess. She smoked one 
pack of cigarettes daily. She was a native of Cape 
Verde but had lived most of her life in Massachu-
setts. She lived with her husband and was not em-
ployed because of her illness. Both of her parents 
had died of human immunodeficiency virus (HIV) 
infection. She was allergic to sulfa medications. 
In addition to anti biotics and diphenylhydantoin, 
her medications included fluoxetine, pantoprazole, 
prednisone (30 mg daily), lorazepam, a nicotine 
patch, and a fentanyl patch for the pain in her arm. 
On examination, the patient was not in acute 
distress and answered questions appropriately. 
The temperature was 37.4°C, the pulse 100 beats 
per minute, the blood pressure 98/63 mm Hg, and 
the respirations 16 per minute; oxygen saturation 
was 100% while she was breathing ambient air. 
She had oral thrush and a blistering lesion consis-
tent with herpes on her lower lip. The remainder 
of the general physical examination was normal. 
On neurologic examination, she was alert and ori-
ented, with normal attention and speech; short-
term memory was mildly impaired. There was 
slight flattening of the right nasolabial fold; the 
other cranial nerves were normal. The motor 
strength was 4+/5 in the right arm and was oth-
erwise normal. Deep tendon reflexes were 3+ in 
the right arm and 2+ elsewhere; there was an ex-
tensor right plantar response. Sensation was nor-
mal. The gait was narrow-based, with small steps, 
and she had difficulty with tandem gait. The Rom-
berg test was negative. Levels of serum electrolytes, 
amylase, and lipase and tests of coagulation and 
renal function were normal. Serologic testing for 
antibodies to toxoplasma, histoplasma, cryptococ-
cus, blastomyces, coccidioides, bartonella, brucella, 
Coxiella burnetii, HIV, Borrelia burgdorferi, and Lyme 
disease and nucleic acid testing of blood for Tro-
pheryma whippelii were negative. Lumbar puncture 
was performed (Table 1); stains and cultures for 
bacteria and fungi were negative, as was nucleic 
acid testing for cytomegalovirus and varicella–zos-
ter, Epstein–Barr, herpes simplex type 1 and 2, and 
JC viruses. Results of other tests are summarized 
in Table 1.
Repeated MRI of the brain with T2-weighted 
and fluid-attenuated inversion recovery (FLAIR) 
images the next day confirmed the presence of 
an area of hyperintensity involving the posterior 
left frontal and parietal lobe white matter, with 
patchy enhancement at the superior margin of the 
lesion. Levetiracetam, pyrimethamine, leucovorin 
(folinic acid), dapsone, ampicillin, and fluconazole 
were added, and diphenylhydantoin was discon-
tinued. During the next 5 days, the temperature 
rose intermittently to 40.0°C. Repeated MRI on 
the fourth hospital day showed slightly increased 
enhancement but no change in the size of the le-
sion. Magnetic resonance spectroscopy showed 
a normal ratio of choline to creatine and the pres-
ence of a lactate peak. Computed tomographic 
(CT) scanning of the chest and abdomen showed 
no abnormalities. Repeated lumbar puncture (Ta-
ble 1) showed no evidence of malignant cells on 
cytologic examination, and cultures for nocardia 
and listeria were negative.
The patient continued to have joint pain and 
severe headaches and required narcotics for pain 
control. On the sixth hospital day, CT scanning 
of the brain showed a heterogeneously enhanc-
ing lesion in the posterior aspect of the left fron-
tal lobe. A stereotactic biopsy of the brain was 
performed, and microscopical examination of the 
biopsy specimen showed a subacute cerebritis that 
was more florid than typical lupus cerebritis; rare 
cells with prominent nucleoli were present that 
were thought to be histiocytes; special stains and 
immunohistochemical staining for bacteria, myco-
bacteria, fungi, varicella–zoster and herpes simplex 
viruses, and toxoplasma and nucleic acid testing 
for toxoplasma and bartonella DNA were negative. 
Results of laboratory tests are shown in Table 1. 
Lupus flare was diagnosed, and the patient was 
treated with prednisone at a dose of 60 mg daily.
During the next week, intermittent fevers con-
tinued; results of laboratory tests are listed in Ta-
ble 1. Repeated MRI examination of the brain with 
T2-weighted images on the 12th and 16th hospi-
tal days showed enlargement of the lesion in the 
left parietal lobe, with increased mass effect and 
surrounding edema, and new, nonenhancing, hy-
perintense lesions within the right caudate and 
corona radiata, right posterior frontal subcorti-
cal white matter, left anterior frontal gyrus, left 
lentiform nucleus, left occipital lobe, and left an-
terior thalamus. Magnetic resonance perfusion 
performed 3 days later showed decreased cere-
bral blood flow and cerebral blood volume in the 
left posterior frontal and anterior left parietal 
lobes. Positron-emission tomographic (PET) scan-
ning of the brain showed mixed foci of hypo-
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metabolism and hypermetabolism in the areas 
of abnormality detected on MRI; the areas of hy-
permetabolism suggested a malignant condition. 
Lumbar puncture was repeated (Table 1); repeated 
cultures were negative. West Nile virus nucleic 
acid, St. Louis and eastern equine encephalitis anti-
bodies, and toxoplasmosis antibodies were not de-
tected.
During the next week, the patient’s tempera-
ture rose intermittently to 40.0°C. The patient be-
came less alert, with psychomotor slowing, dys-
phasia, dysarthria, naming slowness, and the new 
onset of right–left confusion. Motor strength on 
the right side decreased to 4/5 in the leg, 3/5 in the 
upper arm, and 2/5 in the distal arm. Repeated MRI 
on the 22nd hospital day showed no change. Anti-
microbial management was changed to include 
atovaquone and clindamycin. An open biopsy of 
the brain on the 26th hospital day showed granu-
lomatous inflammation, coagulative necrosis, and 
granulation tissue; special stains and cultures for 
microorganisms were negative.
On the 40th hospital day, the patient had a 
headache and was lethargic. She followed com-
mands but did not speak. Strength in the right arm 
and leg and muscle tone in the right arm were 
decreased. An MRI of the brain showed an in-
crease in the size and number of lesions and pos-
sible leptomeningeal involvement. A transesopha-
geal echocardiogram obtained the next day showed 
no vegetations. The patient became progressively 
more somnolent. A magnetic resonance cerebral 
angiogram performed on the 43rd hospital day 
showed progression of the lesions. A conven-
tional cerebral angiogram showed no evidence 
of vasculitis. Lumbar puncture was repeated on 
the 45th day (Table 1), and caspofungin and vori-
conazole were added to her medications. On the 
46th day, the patient was mute but followed com-
mands. Repeated T2-weighted MRI showed pro-
gression of the existing lesions and a new, en-
hancing, hyperintense focus in the right superior 
frontal gyrus.
A trial of intravenous pulse methylpredniso-
lone (Solu-Medrol, Pfizer) at a dose of 1 g per day 
for 3 days was begun on the 51st hospital day. On 
the 52nd day, the patient was obtunded, with decor-
ticate posturing and increased respiratory effort; 
the trachea was intubated, and she was transferred 
to the neurologic intensive care unit. Her antimi-
crobial regimen consisted of caspofungin, voricon-
azole, clindamycin, atovaquone, meropenem, van-
comycin, and pyrimethamine. A urine culture was 
positive for vancomycin-resistant enterococci, and 
a sputum culture was positive for Klebsiella pneu-
moniae and Pseudomonas aeruginosa; linezolid and 
cefepime were added to her medications.
On the 54th hospital day, the patient’s pupils 
were fixed and dilated. CT scanning of the brain 
showed new areas of hypoattenuation in the right 
hemisphere and transtentorial and uncal hernia-
tion. An intracranial pressure monitor was placed, 
and the intracranial pressure on Licox insertion 
was 50 mm H2O. Despite therapy with manni-
tol and induced hypertension, the patient’s in-
tracranial pressure increased to 130 mm H2O, and 
the cerebral perfusion pressure was less than 
10 mm Hg. She met clinical criteria for brain 
death by the evening of that day.
An autopsy was performed.
differ en ti a l Di agnosis
Neurologic Localization of the Lesion
Dr. Jang-Ho J. Cha: The first task of the neurologist 
who is treating a patient with a neurologic defi-
cit is to locate the responsible lesion in time and 
space. When I first saw this patient, she had had 
intermittent numbness of the tongue and slurred 
speech for several months. Although I am aware 
of the diagnosis in this case, these symptoms sug-
gest the presence of a spatially fixed lesion in the 
brain, with a number of possible localizations. The 
symptom of numbness is ambiguous, since it can 
imply either altered sensation or motor difficulty. 
The presence of slurred speech makes a motor 
problem more likely.
The transient shaking of the right arm that 
occurred 6 days before admission was most likely 
due to a focal seizure. This information is an im-
portant clue to localization, pointing to a lesion 
within the cortical surface of the left hemisphere. 
The area of the motor cortex that controls the arm 
is located near the area that controls the tongue 
and face; therefore, the numbness of the tongue, 
the facial weakness, and the seizure and weakness 
involving the right arm can be attributed to a sin-
gle lesion most likely located within the junction 
The New England Journal of Medicine 
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of the gray and white matter, an area where the 
clinical manifestation of lesions is likely to be sei-
zures. Since language is largely preserved, there 
is no widespread damage within the left hemi-
sphere. However, the fact that there is an extensor 
plantar response of the right toe suggests that this 
is a large lesion, since the area of the motor cor-
tex that controls the leg and foot is located some 
distance from the area that controls the face and 
arm. May we see the imaging studies?
Dr. Mark E. Mullins: MRI scans of the brain ob-
tained on the second hospital day (Fig. 1A and 1B) 
show a dominant lesion within the perirolandic 
region of the left hemisphere, associated with 
some contrast enhancement, hyperintensity on 
FLAIR and T2-weighted images, and mild swell-
ing. Some areas of restricted diffusion, which is 
consistent with vasogenic and cytotoxic edema, 
are associated with the dominant lesion. On the 
fourth hospital day, a repeated examination with 
spectroscopy showed diffusely decreased peaks 
within the areas of abnormal enhancement, sug-
gesting some neuronal loss. The ratio of choline 
to creatine was approximately 1, a result suggest-
ing that a tumor was not present.
Scans from repeated brain MRI on the 12th 
hospital day (Fig. 1C and 1D) show prominent 
changes in the dominant lesion, including hyper-
intensity on a T1-weighted image and decreased 
signal intensity on the gradient–echo sequence, 
indicating the presence of hemorrhage. The lesion 
now has the appearance of a space-occupying 
enhancing lesion surrounded by a large area of 
edema.
PET scans of the brain obtained on the 19th 
hospital day show mixed hypermetabolism and 
hypometabolism in the dominant lesion (see 
Fig. 1 of the Supplementary Appendix, available 
with the full text of this article at www.nejm.
org); these findings are consistent with cerebri-
tis but also could suggest a neoplasm. The num-
ber of lesions has increased dramatically as com-
pared with previous images. FLAIR images from 
another MRI scan (Fig. 1E and 1F) now show 
multiple areas of intraparenchymal swelling and 
hyperintensity on FLAIR images, in addition to 
the original lesion. The findings on MRI perfu-
sion scans did not suggest the presence of a 
brain tumor.
A B
C D
E F
Figure 1. MRI Scans of the Brain.
A FLAIR image obtained on the second hospital day shows mild swelling 
and hypointensity in the left frontoparietal, perirolandic region, which is 
most consistent with edema (Panel A, arrows), with subtotal enhancement 
on a T1-weighted image obtained after gadolinium enhancement (Panel B, 
arrows). A FLAIR image on the 12th hospital day shows a left frontoparietal 
lesion that has increased in size (Panel C, arrows), with enhancement and 
surrounding edema on a T1-weighted image obtained after gadolinium en-
hancement (Panel D, arrows). FLAIR images of the brain on the 19th hospi-
tal day (Panels E and F) show multifocal, parenchymal hyperintensities that 
are most consistent with edema; most of these lesions (arrows) are new. 
There is involvement of the deep gray matter, subcortical white matter, and 
corpus callosum.
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Radiologic Differential Diagnosis
The findings on the imaging studies are most 
consistent with cerebritis. Ongoing seizure activ-
ity can produce similar results, which may be the 
primary disorder or may occur in combination 
with other underlying conditions. The findings on 
PET scans suggest that this is not a typical bacte-
rial infection.1 Inflammatory disorders, includ-
ing lupus cerebritis and sarcoidosis, should also 
be considered. Atypical tumors such as lympho-
ma or glioma may be included in the differential 
diagnosis in a case like this, when no other diag-
nosis is apparent. The imaging findings do not 
suggest simple ischemia or infarction.
Dr. Jonathan Kay: In this patient with SLE and 
the new onset of fever, seizures, weakness, and a 
brain lesion, the major question for the rheuma-
tology consultants was whether these were the 
result of lupus disease activity itself or of a com-
plication such as infection or a malignant tumor 
such as lymphoma.
Lupus Disease Activity
Fever is one of the most common clinical mani-
festations of SLE, and disease activity accounts for 
more than 66% of febrile episodes in patients with 
this condition.2 This patient did not have shaking 
chills or an elevated absolute neutrophil count, but 
she did have elevated titers of anti–double-strand-
ed DNA and anti–ribosomal P antibodies, leuko-
penia, and hypocomplementemia — findings that 
are more characteristic of lupus disease activity 
than of infection. Various autoantibodies have been 
associated with neuropsychiatric lupus3-5; this 
patient had anti–double-stranded DNA antibod-
ies and anti–ribosomal P antibodies, and she had 
had elevated IgG anticardiolipin antibodies in the 
past. Anti–double-stranded DNA antibodies cross-
react with NR2 glutamate receptors in the brain,5 
and anticardiolipin antibodies may confer a pre-
disposition to coagulation, resulting in the neuro-
logic consequences of ischemic injury. Anti–ribo-
somal P antibodies have been detected in patients 
with lupus who had psychosis or depression, nei-
ther of which was present in this patient.
Neuropsychiatric SLE
Central nervous system (CNS) involvement in 
SLE6-12 includes inflammation of the brain (cere-
britis) or intracranial blood vessels (vasculitis) and 
ischemic complications of vasculitis.4 The most 
common manifestations are cognitive dysfunction, 
headache, seizures, and psychiatric conditions; 
aseptic meningitis, stroke, encephalopathy, move-
ment disorders, and myelopathy are also seen.3,13,14 
This patient had seizures, cognitive dysfunction, 
and headache.
Parenchymal lesions, which are seen on imaging 
studies in up to 36% of patients, are usually lo-
cated in the periventricular and subcortical white 
matter or corticomedullary junction. These lesions 
are thought to be a consequence of perivascular 
microinfarction. In this patient, however, the neu-
roradiographic appearance of the lesions did not 
suggest ischemia or demyelinating disease, and 
a cerebral angiogram did not show vasculitis.
Infection
Infections are common in patients with SLE,15 
accounting for about 20% of episodes of fever,2 
and are a leading cause of death in hospitalized 
patients.2,16 CNS infection occurs infrequently,17 
most often in patients who have received cortico-
steroid treatment within the previous 6 months 
as well as concurrent immunosuppressive thera-
py with cyclophosphamide, azathioprine, or other 
agents. Our patient had important risk factors 
for infection, including active SLE with lympho-
penia,18 renal involvement, hypoalbuminemia, and 
the receipt of high doses of corticosteroids. She 
had also received other immunosuppressive ther-
apy, including etanercept, a tumor necrosis factor 
(TNF) antagonist that may interfere with the host 
defense against opportunistic infections, includ-
ing Mycobacterium tuberculosis, Histoplasma capsula-
tum, and Listeria monocytogenes.19
Although neuropsychiatric lupus is a possible 
explanation for this patient’s symptoms, her risk 
factors for infection suggested that an unusual 
infection could not be ruled out, even in the pres-
ence of negative cultures and serologic studies for 
potential pathogens.
Dr. Karen Furie: The fulminant nature of this 
patient’s illness, lack of response to immunosup-
pressive therapy, and rapid progression are not 
characteristic features of neuropsychiatric lupus. 
Since the patient was receiving immunosuppres-
sive therapy for an autoimmune disease, possible 
infectious causes included bacterial, viral, fungal, 
and parasitic pathogens; in addition, we consid-
ered neoplastic and demyelinating conditions 
(Table 2).
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Infections in Immunocompromised Patients
Cerebral toxoplasmosis has been reported in pa-
tients with SLE as a result of immunosuppression 
from the disease itself or from disease-modify-
ing agents.20,21 This patient’s clinical course and 
the findings on imaging studies were consistent 
with the diagnosis of Toxoplasma gondii; however, 
biopsy of the brain and serologic tests of the cere-
brospinal f luid were negative. Nevertheless, be-
cause of a strong suspicion for this diagnosis, she 
was treated for toxoplasmosis with dapsone and 
pyrimethamine, since her allergy to sulfa drugs 
precluded treatment with trimethoprim–sulfa-
methoxazole.
Progressive multifocal leukoencephalopathy 
is a demyelinating disease caused by the JC virus, 
affecting immunocompromised hosts. Patients 
with progressive multifocal leukoencephalopa-
thy typically present with rapidly progressive focal 
neurologic deficits, although the onset can be 
subacute, and seizures can occur. Imaging stud-
ies characteristically show nonenhancing lesions 
of the white matter. The clinical scenario in this 
patient was suggestive of progressive multifocal 
leukoencephalopathy; however, the imaging find-
ings were atypical, nucleic acid testing for the JC 
virus was negative, and two brain biopsies did not 
show the characteristic findings.
Patients with CNS cryptococcosis usually pre-
sent with subacute symptoms such as encepha-
lopathy, headache, and fever, and this diagnosis 
would be a consideration in this case. However, 
the results of imaging studies, negative cerebro-
spinal fluid test for cryptococcal antigen, and nega-
tive cerebrospinal fluid culture essentially rule out 
this diagnosis. Patients with neurocysticercosis, 
which is caused by the larval stage of the pork 
tapeworm, Taenia solium, commonly present with 
seizures22,23; headache, altered sensorium, and 
focal deficits have also been described. This pa-
tient was a native of Cape Verde, where neurocys-
ticercosis has been reported.24 However, the acute 
febrile illness and rapid progression are not char-
acteristic of neurocysticercosis, and the imaging 
studies did not support this diagnosis.
Lymphoma
Finally, primary CNS lymphoma is a rare subtype 
of non-Hodgkin’s lymphoma, usually of B-cell ori-
gin, that affects the eyes, brain, and leptomenin-
ges. It occurs more commonly in immunocom-
promised than in immunocompetent persons, 
including patients treated with agents that block 
the activity of TNF.25 Some of the imaging find-
ings in this patient were thought to be consistent 
with lymphoma. However, two biopsies showed no 
evidence of lymphoma. We considered perform-
ing a third biopsy but could not do so because of 
Table 2. Differential Diagnosis of an Enhancing 
Hemispheric Lesion in This Patient.
Lupus
Vasculitis
Lupus cerebritis
Demyelinating disease
Ischemia
Infections
Bacterial
Tropheryma whippelii (Whipple’s disease)
Listeria
Nocardia
Bartonella
Mycobacteria
Viruses
JC virus (progressive multifocal leukoencepha-
lopathy)
Cytomegalovirus
Herpes simplex virus
Varicella–zoster virus
West Nile virus
Eastern equine encephalitis
Protozoa
Toxoplasma gondii
Ameba
Fungi
Candida
Mucormycosis
Cryptococcus
Histoplasmosis
Coccidioidomycosis
Aspergillus
Blastomycosis
Helminths
Schistosomiasis
Neurocysticercosis
Neoplasms
Lymphoma
Glioma
Metastases
Sarcoma
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the rapid deterioration of the patient’s neurologic 
status.
Dr. Cha: Because of the patient’s deteriorating 
condition and her lack of response to a broad spec-
trum of antimicrobial therapies, we were left with 
a presumptive diagnosis of lupus cerebritis. A trial 
of high-dose corticosteroids was initiated in an 
attempt to treat this condition, but her disorder 
worsened and she died.
Cl inic a l Di agnosis
SLE with probable lupus cerebritis.
Possible CNS infection.
Pathol o gic a l Discussion
Dr. E. Tessa Hedley-Whyte: The two brain biopsy spec-
imens showed an inflammatory process, which 
in the first biopsy specimen comprised predomi-
nantly lymphocytes and polymorphonuclear leuko-
cytes, with occasional pale cells that were thought 
to be histiocytes (see Fig. 2 of the Supplementary 
Appendix). The second biopsy specimen showed 
a granulomatous reaction with coagulative ne-
crosis and granulation tissue, but no recogniz-
able organisms.
At autopsy, the entire left hemisphere of the 
brain was disintegrating (Fig. 2A). The thalamus 
A B
DC
Figure 2. Sections of the Brain at Autopsy.
Coronal sections of the formalin-fixed brain show flattening of the gyri and obliteration of the sulci, findings indica-
tive of severe brain swelling, and loss of delineation between gray and white matter (Panel A). The left hemisphere 
(on the left side of the photograph) is disintegrating. The left and right midbrain and caudal left thalamus are hem-
orrhagic. The biopsy site is marked by an arrow. A histologic section of central white matter from the left hemisphere 
contains multiple areas of inflammation and necrosis, predominantly in a perivascular distribution (Panel B, Luxol 
fast blue–hematoxylin and eosin staining for myelin and cells). At a higher magnification, there are perivascular lym-
phocytes, plasma cells, a multinucleated giant cell (black arrowhead), and a few amebas (black arrows) (Panel C, hema-
toxylin and eosin). The inset shows a viable ameba (arrow) in the white matter with only a mild inflammatory response 
(hematoxylin and eosin). There is necrosis of a blood-vessel wall (Panel D, Luxol fast blue–hematoxylin and eosin), 
which is a typical finding in amebic encephalitis. Several disintegrating amebas are mixed with the inflammatory 
cells (arrows).
The New England Journal of Medicine 
Downloaded from nejm.org at UMASS WORCESTER on April 26, 2015. For personal use only. No other uses without permission. 
 Copyright © 2006 Massachusetts Medical Society. All rights reserved. 
case records of the massachusetts gener al hospital
n engl j med 355;25 www.nejm.org december 21, 2006 2687
and the upper brain stem were hemorrhagic and 
necrotic. Lesions were also evident within the cer-
ebellum. Microscopical examination showed peri-
vascular and parenchymal inf lammation with 
multinucleated giant cells, lymphocytes, plasma 
cells, and neutrophils throughout the brain (Fig. 
2B). There were numerous amebas, which are 
easily mistaken for histiocytes (Fig. 2C). Amebas 
were present even in areas that appeared normal 
on gross examination, with only a minor inflam-
matory response. Encysted amebas were present 
in small numbers. A characteristic of amebic en-
cephalitis is the dissolution of the blood-vessel 
walls, which probably accounts for the hemor-
rhage in the most involved areas (Fig. 2D).
The size of the amebas was compatible with 
acanthamoeba, balamuthia, and entamoeba. Ent-
amoeba is not associated with this type of inflam-
matory response and has no capsule. To ascer-
tain whether this organism was acanthamoeba 
or balamuthia, samples of the tissue were sent to 
the Centers for Disease Control and Prevention. 
Immunofluorescence staining of the formalin-
fixed brain tissue with rabbit antibodies to acan-
thamoeba species confirmed the diagnosis of in-
fection with acanthamoeba species (see Fig. 3 of 
the Supplementary Appendix).26 An analysis of 
nucleic acid amplified by means of polymerase 
chain reaction from frozen brain tissue revealed 
the genus-specific amplicon ASA.S1, genotype T1. 
This amplicon has been seen in isolates of acan-
thamoeba obtained from granulomatous amebic 
encephalitis but not from the environment.27,28
The anatomical diagnosis is granulomatous 
amebic encephalitis due to acanthamoeba species. 
The rest of the autopsy showed inactive membra-
nous glomerulonephritis. No amebas were seen 
outside the brain.
The diagnosis of granulomatous amebic en-
cephalitis is notoriously difficult to establish.27 
Even after we knew that the diagnosis was ame-
bic encephalitis, we were not confident that there 
were recognizable amebas in the biopsy speci-
mens. In retrospect, some of the cells identified 
as histiocytes in the specimens were probably 
amebas (see Fig. 2 of the Supplementary Appen-
dix). Three other cases of granulomatous amebic 
encephalitis due to acanthamoeba have been re-
ported in patients with SLE, all diagnosed post 
mortem.29-31
Discussion of M a nagemen t
Dr. Rochelle P. Walensky: Free-living amebas cause 
three types of disease in humans: amebic kera-
titis, primary amebic meningoencephalitis, and 
granulomatous amebic encephalitis. Table 3 com-
pares the characteristics of primary amebic me-
ningoencephalitis and granulomatous amebic 
encephalitis. Our patient had a typical clinical pre-
sentation of granulomatous amebic encephalitis 
due to acanthamoeba species, with subacute to 
long-term onset of symptoms related to a space-
occupying lesion, including seizures, focal nerve 
deficits, and alteration in mental status. Death gen-
erally occurs within weeks after the onset of symp-
toms, often from herniation of the brain due to 
increased intracranial pressure; this was the case 
with the patient under discussion.32
Acanthamoeba species presumably enter the 
CNS through hematogenous spread from a usu-
ally transient primary infection in the lungs, skin, 
or paranasal sinuses in an immunocompromised 
host. The diagnosis is challenging, since acan-
thamoeba species are rarely isolated from cerebro-
spinal fluid33 and serologic testing is not useful.34 
Brain biopsy, which was nondiagnostic on two oc-
casions in this patient, is the only way to make a 
definitive diagnosis. The diagnosis is most often 
made on postmortem examination, as in this case.
Table 3. Comparison of the Features of Granulomatous Amebic Encephalitis and Primary Amebic Meningoencephalitis.
Characteristic Granulomatous Amebic Encephalitis Primary Amebic Meningoencephalitis
Infective agent Acanthamoeba species 
Balamuthia mandrillaris
Naegleria fowleri
Predisposition Occurs in immunodeficient persons 
Associated with chronic debilitating illness
Occurs in healthy persons
Associated with exposure to contaminated water
Clinical course Subacute Acute, with death occurring within days
Pathological  findings Cysts and trophozoites present
Hemorrhagic necrosis
Vasculitis
Inflammation with or without granulomas
Only trophozoites present
Hemorrhagic necrosis
Purulent meningoencephalitis
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In nearly all cases of successful treatment of 
infections due to acanthamoeba species, the dis-
ease is localized to the skin or sinuses, without CNS 
involvement. In rare cases, patients with granulo-
matous amebic encephalitis have survived, usually 
when a single brain lesion could be excised.32,35 
For this patient, there would have been limited 
therapeutic options had the diagnosis been made 
before death.35 Most available antimicrobial agents 
are amebostatic rather than amebicidal, are too 
toxic, or do not penetrate the CNS.35 The use of 
corticosteroids to decrease intracranial pressure 
may exacerbate immune dysfunction.32
Dr. Kay: Because TNF plays a crucial role in 
granuloma formation, organisms that stimulate 
a granulomatous response, such as M. tuberculosis 
and H. capsulatum, may disseminate with TNF an-
tagonist therapy. Although we do not know the 
timing or duration of etanercept therapy in this 
patient, its use may have predisposed her to dis-
seminated amebic infection by interfering with 
granuloma formation.
A nat omic a l Di agnosis
Granulomatous amebic encephalitis due to acan-
thamoeba species.
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